Zacks Small-Cap Research
Sponsored – Impartial – Comprehensive

December 20, 2019
John D. Vandermosten, CFA
312-265-9588 / jvandermosten@zacks.com

scr.zacks.com
10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606

CEL-SCI Corporation (CVM - NYSE)

Watching and Waiting

Based on our DCF model and a 15% discount rate, CEL-SCI is valued at approximately $19.00 per share. Our model applies a 70% probability of ultimate approval and commercialization for Multikine in head and neck cancer. The model includes contributions from the US, EU and rest of world.

Current Price (12/19/2019)	$8.92
Valuation	**$19.00**

OUTLOOK

CEL-SCI is developing two platforms, Multikine and LEAPS. Multikine is being used in a Phase 3 trial for head and neck cancer while LEAPS is conducting preclinical studies for RA, Pandemic Flu and breast cancer. After recent catalysts related to favorable decision against a former CRO and the lifting of a clinical hold on Multikine, investors are anticipating a near term conclusion of the Phase 3 trial and readout on the head and neck cancer study.

Multikine is an immuno-oncology biologic that contains human blood-derived cytokines that are thought to enhance the body's natural defenses against cancer. For the lead indication, SCCHN, it is used prior to and in conjunction with SOC, which includes surgery, radiation and chemotherapy. LEAPS is a peptide epitope delivery technology that can direct immune response. It is appropriate for diseases where antigenic epitope sequences have been identified.

Our valuation assumes a 2020 FDA approval of Multikine for head and neck cancer and a 2021 launch of the compound in the US, followed by a subsequent launch in the EU and global availability by 2022 that will be achieved through the efforts of partners.

SUMMARY DATA

52-Week High	**9.93**
52-Week Low	**2.37**
One-Year Return (%)	**224**
Beta	**3.0**
Average Daily Volume (sh)	**568,526**
Shares Outstanding (mil)	**35.4**
Market Capitalization ($mil)	**316**
Short Interest Ratio (days)	**17.9**
Institutional Ownership (%)	**10.1**
Insider Ownership (%)	**4.9**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2019 Estimate	**N/A**
P/E using 2020 Estimate	**N/A**
Zacks Rank	**N/A**

Risk Level	**Above Average**
Type of Stock	**Small-Growth**
Industry	**Med-Biomed/Gene**

ZACKS ESTIMATES

Revenue

(In millions of USD)

	Q1 (Dec)	Q2 (Mar)	Q3 (Jun)	Q4 (Sep)	Year (Sep)
2018	$0.1 A	$0.1 A	$0.1 A	$0.1 A	$0.5 A
2019	$0.1 A	$0.2 A	$0.1 A	$0.1 A	$0.5 A
2020					$0.4 E
2021					$35.6 E

Earnings per Share

	Q1	Q2	Q3	Q4	Year
2018	-$0.53 A	-$0.31 A	-$0.36 A	-$0.61 A	-$1.87 A
2019	$0.04 A	-$0.22 A	-$0.37 A	-$0.14 A	-$0.71 A
2020					-$0.45 E
2021					$0.35 E

© Copyright 2019, Zacks Investment Research. All Rights Reserved.

WHAT'S NEW

Fiscal Year 2019 Operational and Financial Results

CEL-SCI Corporation (NYSE: CVM) reported fiscal 2019 operational and financial results for the twelve month period ending September 30, 2019. The company provided an update of the Phase III Multikine trial, highlighting the two Independent Data Monitoring Committee (IDMC) meetings that have taken place this year. New data was presented for LEAPS for rheumatoid arthritis and influenza. Strong share price performace led to CEL-SCI's selection as a member of the Russell 3000 index in July and warrants have been exercised, providing cash flows to support end of period cash and equivalents of $8.4 million.

During its fiscal year 2019, CEL-SCI recognized grant income of $463,000, which was related to the LEAPS platform and the development of a rheumatoid arthritis vaccine. This was similar to the amount recognized in FY:19. Research and development expenses rose to $12.7 million for 2019, compared to a restated $10.9 million in 2018. General and administrative expenses were $8.0 million in the year, up from a restated $6.3 million in the prior year.[1] Increased operational expenses are attributed to higher payments to contract research organization (CRO) ICON Inc. and an increase in employee stock compensation costs. Other income was $73,000, loss on derivative instruments was ($760,000) due to share price increases and other non operating gain of $546,000 was related to payments to Ergomed for CRO services. After subtracting ($1.8) million in interest expense, CEL-SCI reported a net loss of ($22.1) million, or ($0.71) per share. Removing the gain on derivative instruments and other non-operating gains had a negligible impact on net income and no impact on EPS. This compares to our estimated loss of ($0.64) per share with the difference attributable to other income.

Cash balance as of September 30, 2019 stands at $8.4 million, a $1.9 million decline from year end 2018 levels. CEL-SCI benefitted from $14.5 million in financing cash flow from exercise of warrants which partially offset cash burn of ($16.5) million. CEL-SCI continues with no debt.

The Last Review?

CEL-SCI announced its latest IDMC review for the IT MATTERS Phase III Multikine study for head and neck cancer in mid-October. We believe that the longer than expected duration of the trial combined with the IDMC recommendation to continue its progress have positive implications for the safety and efficacy of the investigational drug.

We note a number of precedents of IDMC reviews being followed by the halt of a trial due to futility. Bioigen's (NASDAQ: BIIB) aducanumab, NuCana's (NASDAQ: NCNA) Acelarin and the Transgene/SillaJen's Pexa-Vec Phase III trials were all halted in 2019. These terminations show the willingness of monitoring committees to shut down a study if it fails to show results. While many examples can be found for trials ending early for futility, it is difficult to find examples of a trial being stopped early for exceptional efficacy.

We see the latest IDMC meeting as a favorable milestone and believe the results justified an increase in our probability of success estimate, although there could be other unexpected factors that are delaying the report of the target number of events. The delay in reported events could be attributed to higher than expected dropouts, a greater mix of Stage III vs. Stage IVa patients enrolled, or a higher proportion of a less fatal subtype of head and neck cancer among other unknown and unexpected factors. A slip by Ergomed in a September 25th slide deck suggested that the IT MATTERS trial was 96% complete, and by extension lacks only an additional 11 or 12 events in the active and comparitor arm to achieve completion. While the statistic disappeared in a later version of Ergomend's slide deck, we anticipate the 298th event to be just around the corner.

CEL-SCI provided some data in a September 10th slide presentation which updated data specific to the study population enrolled in CEL-SCI's Phase III trial. In its original study filing with the U.S. National Library of Medicine eight years ago, CEL-SCI cited median 3-year overall survival (OS) for their patient population as between 52 and 55% and five year OS as 43%. These statistics are somewhat out of date, especially considering the advances that have been made in immuno-oncology since the trial began.

[1] Restatements were related to classification of operating expenses. ~$1.5 million of 2018 G&A expenses were moved to R&D. Total operating expenses remained the same for FY:18.

The updated data was sourced from the Surveillance, Epidemiology and End Results (SEER) program, which is part of the National Institute of Health (NIH) National Cancer Institute (NCI). The group collects and publishes cancer incidence and survival data that represents over a third of the US population. CEL-SCI commissioned an external statistical group to analyze the data and determine an OS estimate for the specific population Multikine is addressing. Below we provide a summary of the data as provided by CEL-SCI:

Exhibit I – Overall Survival (OS) Estimates for Multikine Study Population[2]

Year	OS Estimate	95% Confidence Bound
1	71.42%	(69.84%, 72.92%)
2	53.86%	(52.09%, 55.59%)
3	**46.59%**	(44.74%, 48.42%)
4	41.98%	(40.02%, 43.93%)
5	**36.75%**	(34.475%, 39.03%)

Compared to the initial data cited by CEL-SCI, OS is lower in the updated population, which seems to be at odds with the OS trend for cancer types in general. As mentioned above, the three year OS was from 52 to 55%, while the updated SEER[3] data demonstrated an OS of 45 to 48%. At the five year mark, OS was cited as 43% in the U.S. National Library of Medicine filing, as compared to the updated data which indicates a 37% five-year OS. While it is difficult to say why head and neck cancer mortality rates have worsened over time, some ideas have crossed our collective mind. One may be the dramatic decrease in smoking over the last decades, which is highly correlated with head and neck cancer. Changing the prevalence of this risk factor could have impacted the characteristics of the head and neck population. Other factors could include changes in underlying behaviors and disease such as alcohol use, Epstein-Barr Virus (EBV) and Human Papilloma Virus (HPV). In any case, as the population was randomized, both the active and comparitor arms should reflect the same characteristics and not impact the measurement of benefit from Multikine. Our goal with this updated SEER data analysis was to estimate how many deaths should have occurred if the Multikine trial population matched the control arm.

If one assumes the median OS as indicated in the SEER data,[4] for the ~797 patients in the SOC and Multikine + ciz + SOC arms,[5] this suggests that there should be over 460 events so far. If we assume median OS in the SOC arm and a 10% improvement in OS in the Multikine arm, this suggests about 437 events in September 2019. Even under our conservative assumptions of patients in each cohort being enrolled at the end of the cohort period and at the highest bound of the 95% confidence interval for OS and a 30% improved efficacy, there should have already been over 60 events more than required to complete the IT MATTERS trial. While the longer than expected trial duration does increase the likelihood that Multikine is extending OS, it also suggests that there may be other factors also reducing the number of events as compared to what is expected based on the SEER dataset.

We place a lot of confidence in the IDMC team and their focus on safety and efficacy for the patient. The goal of any IDMC is to ensure that the interests of the patients are well served, the risk benefit ratio is appropriate and the scientific integrity of the trial is maintained. They have the responsibility to recommend early termination for a trial if interim data is sufficiently compelling for the medicine is either notably effective or harmful to the patients.

We believe the threshold required to recommend stopping the trial early for efficacy is extremely high, even when data are supportive. According to a study published by Pak, et al.[6], about 0.5% of trials that are terminated early are done so for success. When interim analyses suggest that patient health is at risk or the medicine under

[2] Source: CEL-SCI Corporate Presentation, September 10, 2019.
[3] The SEER database estimates includes the same population enrolled in the IT MATTERS trial who received SOC. This includes oral cavity (anterior tongue [not base of tongue], cheek, floor of the mouth and soft palate. Over 3,000 patients were included in the study population to calculate 5 year survival.
[4] With a whole host of simplifying, conservative assumptions. Numbers for year cohorts provided by company are all assumed to occur at the end of the period. Five year survival is applied to all patients who have been in the trial for five or more years
[5] This assumes median OS for both arms and zero additional benefit from Multikine.
[6] Pak, TR; Rodriguez, MD; Roth, FP; Why Clinical Trials Are Terminated. bioRxiv. July 2, 2015. https://www.biorxiv.org/content/10.1101/021543v1

investigation is not working, the threshold is lower for recommending early termination as demonstrated in the examples above for Biogen, NuCana and Transgene/SillaJen. Therefore we see an asymmetric relationship between trials halted for superior efficacy and those halted for futility.

Using the SEER data analysis and some conservative assumptions,[7] we estimated the number of events that should have occurred assuming the control arm matches the SEER analysis and the Multikine arm demonstrates a 30% improvement in OS. We apply this to the upper bound (fewer deaths) of the confidence interval in Exhibit I and calculate a result of over 360 deaths as of September 2019.

The IT MATTERS trial has not yet ended, indicating that the 298 required events have not yet occurred. The events required for trial completion seems to be outside the confidence interval bounds suggested by the SEER data analysis, our own research cited in our initiation and other analyst research. It appears most likely to us that the group enrolled in the trial may be an outlier in terms of OS ***and*** Multikine is improving OS. Applying standard logic to the longer than expected trial and noting that that IDMC has allowed the trial to continue, it stands to reason that the longer the trial lasts, the more likely it is that Multikine is increasing OS. Combined with the IDMC's recommendation that the trial continue until the appropriate number of events have occurred, we maintain our optimism on the success of the IT MATTERS trial.

Investment Thesis

We remind investors of the key tenets that support ownership in CEL-SCI which are discussed in detail in our initiation:

- **Compelling preclinical and clinical data supportive of Multikine's effective mechanism of action**
- **Multkine is complementary to first line "intent to cure" SOC, in contrast to other monotherapies**
- **Multikine is administered prior to SOC, synchronizing with the preparation period prior to surgery**
- **Differentiated approach that employs multiple proteins for cancer cell identification & destruction**
- **Proprietary manufacturing process, patent protection and anticipated biologics exclusivity**
- **CEL-SCI maintains operation and control of its Multikine manufacturing facility**
- **Multikine source material is abundant human PBMCs**
- **Favorable drug safety profile with no reported drug-related adverse events**
- **Biologic eligible for 12 years of exclusivity in United States**
- **Global rights to intellectual property**
- **Pipeline includes LEAPS platform with additional indications**
    - **Rheumatoid Arthritis**
    - **Pandemic Flu**
    - **Breast Cancer**

Summary

CEL-SCI is in the final stages of the Multikine IT-MATTERS trial and we believe final events will occur in the next months, based on publically available information. As of calendar year end we are in wait and see mode, waiting for an announcement of trial conclusion. If Multikine is able to meet or surpass its primary endpoint of 10% increase in overall survival as compared to standard of care alone, we see substantial upside to current levels. We maintain our target price of $19.00.

[7] We assume that all enrollees enrolled between 2011 and 2014 have been in the trial for five years, patients enrolled in 2015 have been enrolled for four years, and patients enrolled in 2016 have been enrolled for three years.

PROJECTED FINANCIALS

CEL-SCI Corporation - Income Statement

CEL SCI Corporation	2018 A	Q1 A	Q2 A	Q3 A	Q4 A	2019 A	2020 E	2021 E
Total Revenues	**$0.5**	**$0.1**	**$0.2**	**$0.1**	**$0.1**	**$0.5**	**$0.4**	**$35.6**
YOY Growth	*590%*	*11%*	*14%*	*5%*	*-39%*	*-3%*	*-14%*	*8790%*
Research & Development	$9.4	$3.1	$2.5	$2.3	$4.7	$12.7	$13.0	$6.0
General & Administrative	$7.8	$2.0	$1.9	$3.0	$1.0	$8.0	$8.2	$8.4
Income from operations	($16.8)	($5.0)	($4.3)	($5.2)	($5.6)	($20.2)	($20.8)	$21.1
Other Income	($8.6)	$6.7	($1.7)	($6.4)	$1.2	($0.1)	$0.0	$0.0
Interest Expense	($6.5)	($0.4)	($0.5)	($0.4)	($0.4)	($1.8)	($1.6)	($1.6)
Pre-Tax Income	($31.8)	$1.2	($6.4)	($12.1)	($4.8)	($22.1)	($22.4)	$19.5
Provision for Income Tax	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Tax Rate	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*
Net Income	**($31.8)**	**$1.2**	**($6.4)**	**($12.1)**	**($4.8)**	**($22.1)**	**($22.4)**	**$19.5**
Net Margin								
Reported EPS	**($1.87)**	**$0.04**	**($0.22)**	**($0.37)**	**($0.14)**	**($0.71)**	**($0.45)**	**$0.35**
YOY Growth								
Basic Shares Outstanding	17.00	27.99	29.11	33.05	34.55	31.17	50.00	55.00

Source: Company Filing // Zacks Investment Research, Inc. Estimates

© Copyright 2019, Zacks Investment Research. All Rights Reserved.

HISTORICAL STOCK PRICE

CEL-SCI Corporation – Share Price Chart



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, John Vandermosten, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.

Zacks SCR has received compensation from the issuer directly, from an investment manager or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

© Copyright 2019, Zacks Investment Research. All Rights Reserved.